• Inborn errors of metabolism

Zemaira Generic Name & Formulations

General Description

Alpha1-proteinase inhibitor (human) 1000mg, 4000mg, 5000mg; per vial; lyophilized pwd for IV infusion after reconstitution; preservative-free.

How Supplied

Single-use vial—1 (w. diluent + filter transfer set)


Zemaira Indications


For chronic augmentation and maintenance therapy in adults with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.

Zemaira Dosage and Administration


Give by IV infusion at a rate of 0.08mL/kg/min. 60mg/kg once weekly. Monitor infusion rates and clinical state closely during infusion. Reduce rate or discontinue if adverse reactions occur; resume at lower rate if subside.


Not established.

Zemaira Contraindications


History of anaphylaxis or severe systemic response to A1-PI products. IgA deficiencies with known antibodies against IgA.

Zemaira Boxed Warnings

Not Applicable

Zemaira Warnings/Precautions


Not for lung disease where severe A1-PI deficiency has not been established. Monitor for hypersensitivity reactions; discontinue immediately if anaphylaxis or severe reactions occur. Have epinephrine and other supportive therapy readily available. Contains human plasma; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jakob disease). Pregnancy. Nursing mothers.

Zemaira Pharmacokinetics

See Literature

Zemaira Interactions

Zemaira Adverse Reactions

Adverse Reactions

Headache, sinusitis, upper respiratory infection, bronchitis, asthenia, cough increased, fever, inj site hemorrhage, rhinitis, sore throat, vasodilation; hypersensitivity reactions.

Zemaira Clinical Trials

See Literature

Zemaira Note

Not Applicable

Zemaira Patient Counseling

See Literature